BidaskClub upgraded shares of Albireo (NASDAQ:ALBO) from a sell rating to a hold rating in a research note issued to investors on Thursday.
Other analysts have also recently issued reports about the company. ValuEngine upgraded Albireo from a sell rating to a hold rating in a research report on Friday, February 2nd. Needham & Company LLC raised their target price on Albireo to $50.00 and gave the company a buy rating in a research report on Friday, February 2nd. Wedbush reiterated an outperform rating and set a $63.00 price target on shares of Albireo in a research report on Wednesday, March 28th. Jefferies Group assumed coverage on Albireo in a research report on Friday, April 20th. They set a buy rating and a $50.00 price target on the stock. Finally, Zacks Investment Research cut Albireo from a buy rating to a hold rating in a research report on Wednesday, January 17th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $57.60.
ALBO opened at $32.86 on Thursday. Albireo has a 12 month low of $15.31 and a 12 month high of $39.87. The company has a market capitalization of $392.41 million, a P/E ratio of -10.43 and a beta of 1.61.
Albireo (NASDAQ:ALBO) last posted its earnings results on Thursday, May 17th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the consensus estimate of $3.75 by ($3.90). The company had revenue of $11.20 million during the quarter, compared to analysts’ expectations of $55.33 million. equities analysts anticipate that Albireo will post 0.85 earnings per share for the current year.
Several hedge funds have recently modified their holdings of ALBO. Wells Fargo & Company MN increased its position in shares of Albireo by 282.1% during the 4th quarter. Wells Fargo & Company MN now owns 6,350 shares of the biopharmaceutical company’s stock valued at $162,000 after purchasing an additional 4,688 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of Albireo during the 4th quarter valued at $216,000. Artal Group S.A. acquired a new position in shares of Albireo during the 4th quarter valued at $7,680,000. Sectoral Asset Management Inc increased its position in shares of Albireo by 53.6% during the 4th quarter. Sectoral Asset Management Inc now owns 242,803 shares of the biopharmaceutical company’s stock valued at $6,216,000 after purchasing an additional 84,776 shares during the period. Finally, Perceptive Advisors LLC increased its position in shares of Albireo by 56.2% during the 4th quarter. Perceptive Advisors LLC now owns 1,320,000 shares of the biopharmaceutical company’s stock valued at $33,792,000 after purchasing an additional 475,000 shares during the period. Institutional investors own 29.35% of the company’s stock.
Albireo Company Profile
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase II clinical trial for treating progressive familial intrahepatic cholestasis and primary biliary cholangitis.
Receive News & Ratings for Albireo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo and related companies with MarketBeat.com's FREE daily email newsletter.